middle.news
Why Did the FDA Deny Fast Track for Neurizon’s ALS Drug NUZ-001?
8:56am on Friday 2nd of January, 2026 AEDT
•
Biotechnology
Read Story
Why Did the FDA Deny Fast Track for Neurizon’s ALS Drug NUZ-001?
8:56am on Friday 2nd of January, 2026 AEDT
Key Points
FDA denies Fast Track Designation for NUZ-001, citing need for more clinical data
NUZ-001 targets TDP-43 aggregation, a key mechanism in ALS progression
Advancement into HEALEY ALS Platform Trial operational phases underway
Patient enrolment expected early 2026 in pivotal Phase 2/3 trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Neurizon Therapeutics (ASX:NUZ)
OPEN ARTICLE